Corporate Presentation October, 2011

TAKE Solutions Ltd. Enabling Business Efficiencies

TAKE: Technology, Analytics & Knowledge for the Enterprise

2

Contents

TAKE – At A Glance

Business Model & Market Potential

Competencies

− Life Sciences

− Supply Chain Management

Financials

Growth Strategies & Key TAKEaways

Appendix

3

TAKE Solutions – At A Glance

Headquartered in Chennai, India, TAKE Solutions Ltd. delivers technology, services and expert advice in Life Sciences and Supply Chain Management domains

Strong presence in US, Europe and Middle East Asia: US contributes approx. 2/3 of revenue

Serves over 150 of the top 1,000 Fortune companies

CMMi Level 5 and PCMM Level 3 accredited company

Corporate Sponsor of Clinical Data Interchange Standards Consortium (CDISC) and ACI has a Registered Solution Provider (RSP) status

Recognitions:

TAKE is ranked Leader in the life science R&D IT outsourcing market by IDC, a premier global provider of market intelligence and advisory services IT markets

Ranked first by a premier global analyst firm, for industry expertise and overall customer satisfaction in Life Sciences domain

2011 Supply and Demand Chain Executive 100 List

“Editors’ Pick” Distinction by Consumer Goods Technology Magazine

We serve 400+ clients through 14 offices globally with 1,100+ employees

Life Sciences: Celgene, Eisai, Johnson & Johnson, Merck, Neuromed, Novartis, Pfizer, Roche, Sanofi Aventis

SCM: Applied Materials, Alcoa, GE Group, Honeywell, Panasonic, ITC, Pepsi, Transocean, Xerox

About TAKE Marquee Clients

Financials

Over the last five years, revenue has grown at CAGR of 61% while net profit has grown at CAGR of 69%

0

30

60

90

120

FY05 FY06 FY07 FY08 FY09 FY10 FY11

USD

mn

Revenue Net profit

4

Global Footprint

Chennai, India

Austin & El Paso, TX

Philadelphia, PA

Muscat, Oman

Princeton, NJ

TAKE Solutions Inc. 502 Carnegie Center, Suite 100, Princeton, NJ

USA HQ

TAKE Solutions Ltd. No.8B, Adyar Club Gate Road, Chennai - 600028, India

Global HQ

Riyadh, Jeddah & Al-Khobar

Saudi Arabia

Dubai, UAE

Strong Presence in the US, Middle East Asia and Europe

Hampshire, UK

TAKE Solutions LLP Shriram "The Gateway SEZ", Perungalathur, Chennai, India

Global Delivery Center

Singapore

Kuwait

5

Recognitions and Partnerships

CMMi Level 5 and PCMM level 3

2011: IDC, a global market intelligence firm, ranked TAKE as Leader in the life science R&D IT outsourcing market based on the company’s capabilities and future strategies aligned with what customers will require in three to five years

2011 Supply & Demand Chain Executive 100 list

2010: A premier global analyst firm recognized and ranked TAKE, first among large system integrators for industry expertise & overall customer satisfaction in the Life Sciences Domain

2010 Great Supply Chain Partner by SupplyChainBrain

2010 “Editors’ Pick” Distinction by Consumer Goods Technology Magazine

Global Logistics & Supply Chain Strategies 2010: 100 Great Supply Chain Partners List

2010: Listed in Food Logistics 100 for Fourth Consecutive Year

Manufacturing Business Technology Emerging 40 Vendor List (USA)

Madras Management Association (MMA) Award 2010 for Managerial Excellence in the Services Category

Oracle Gold Partner

SAP Business Objects Gold Partner

Microsoft BIO IT alliance Partner

CDISC Solutions Partner

Microsoft’s Digital Pharma Initiative

Microsoft High Impact Gold partner

Others: Cegedim Relationship Management, Cross Gate, QlikTech, DataMAX, Firefox & Intermec

Certifications & Accreditation Alliances and Partnerships

Business Model &

Market Potential

7

TAKE Solutions – Business Model

DOMAIN Supply Chain Management & Life Sciences

TECHNOLOGY

Service Oriented Architecture (SOA)

Cloud Computing

Virtualization

DELIVERY model

REVENUE model

SaaS On

Premise Business Services

Embedded / RFID / Mobile

Licenses

Maintenance

TRANSACTIONS / SUBSCRIPTIONS

Services

8

TAKE Solutions – Business Model

Balanced: Well distributed across two key verticals - niche offerings addressing multiple end user industries

Wide Portfolio of Offerings: Solutions to address customer needs - Solutions delivered as business services, products and SaaS

Diversified Customer Base: Portfolio of solutions to address customer size - focused approach to large & mid-market customer segment and wider approach to SME segment

Scalable: Platform agnostic solutions to enhance addressable markets and strategic partnerships to drive penetration in areas of specialization

Diversified Revenue Streams: Income from subscription, licensing, royalties, services and AMC leading to a mix of annuity and non annuity revenues

9

Total Addressable Market

1.0

8.0

40.0

0.0

5.0

10.0

15.0

20.0

25.0

30.0

35.0

40.0

45.0

SaaS

On Premise

Business Services

USD

bill

ion

5.7

10.2

0.0

2.0

4.0

6.0

8.0

10.0

12.0

Pre - Approval Post- Approval

USD

bill

ion

Supply Chain Management Life Sciences

Domain Competency

Life Sciences

11

Integrated Solutions & Services

Discovery Development Commercialization

Research Preclinical Phase I Phase II Phase III Phase IV

Technology Solutions

√ √ √ √

CTMS EDC CDMS eDMS eSub CDR/LSH PV

Development Process Services

Individual offerings

SAS Programming Biostatistics Clinical Data

Standardization

Document & Submission Publishing

Milestone based & Multi-milestone Solutions

IND/CTA to NDA Legacy Data Standardization

Document & Submission publishing Data Integration & Clinical Data Repository

Kindly refer the Appendix at the end of the presentation for the meanings of the acronyms used above

Software products - Life Sciences

CDISC

Accelerators

PharmaReady

DMS

PharmaReady

eCTD

PharmaReady

SPL/PLR

PharmaReady

TRMS

SafetyView

PharmaReady

PPM

SAS - Bio Statistics

Framework

Clinical Development

Bio Statistical Programming

Regulatory Submissions

Safety

pvNet

pvConnect

PharmaReady

eTMF

CLINICAL REGULATORY SAFETY

Oracle Life Sciences Oracle Clinical Phase Forward

Siebel CTMS IMPACT

Argus Safety AERS LSH

12

13

Business Services – Life Sciences

Clinical Data Warehouses

ePublishing NDA/IND/ANDA

Document Publishing

Document Archival Safety

Analytics

Safety Signal Detection

Core Data Sheets

Literature Scanning

Case Processing

DMCs

Data Standardization

NDA preparation Biostatistics

Programming

Data Management

Regulatory

Clinical

Safety

Medical Writing & Coding

Trial Master File

Customer A

Therapeutic Area 1

Indication A Indication B

Phase1

Study I

Phase2

Study 1

Therapeutic Area 2

Indication C

Customer B

Therapeutic Area 1

Indication D Indication E

Phase1

Study 1 Study 1 Study 1

Phase2

Study 1 Study 1 Study 1

Therapeutic Area 2

Customer C

Therapeutic Area 1

Customer D

Therapeutic Area 1

Established customer relationships; scalable revenue model

14

Technology + business services

TLFs, Biostatistics, SDTM, ADaM, ISS/ISE, DMCs, SAP, EAC, NDAs

Increasing customer base

Mu

ltip

lyin

g re

ven

ues

15

TAKE Life Sciences - Differentiators

Unique combination of deep domain expertise and technical skills

Market penetration across

Bio-pharmaceutical (branded & generic)

Medical device

CROs

Mature infrastructure across USA and APAC

People

Process

Infrastructure – SAS 70* compliant, validated data center

Strategic partnerships with Oracle and Liquent

TAKE’s differentiated approach to markets

Large and mid-market segment : Functional Service Provider

Small and medium segment : Full Service Provider

* SAS 70 (the Statement on Auditing Standards No. 70) defines the standards an auditor must employ in order to assess the contracted internal controls of a service organization. Service organizations, such as hosted data centers, insurance claims processors and credit processing companies, provide outsourcing services that affect the operation of the contracting enterprise.

16

TAKE Life Sciences - Strategy

Continuously enhancing solutions portfolio to address additional areas of clinical, regulatory and safety leading to larger ticket size of contracts

Reducing dependency on the US market

WCI acquisition to give European footprint

Expansion in other developed geographic like Europe and developing regions like Asia Pacific

Deepening engagement at existing campuses to enable participation in greater proportion of overall R&D spend

Proactively positioning services and offerings in geographies which are mandating regulatory filing in electronic mode

Leveraging partnerships and alliances with Oracle, Liquent & Cegedim Relationship Management to increase product user base as well as expand addressable customer base

17

TAKE assessed as a LEADER in Life Sciences

“TAKE has built a strong list of clients, based on its

deep domain knowledge, willingness to engage

customers as partners, IP-based solutions, and

thought leadership in clinical, regulatory, drug

safety, and other life science areas.”

“TAKE's diverse customer base, broad services

portfolio, strong commitment to life science

industry-specific growth, domain-centric expertise,

and strong customer relationships make TAKE is a

fierce competitor in winning projects that the

company competes for.”

Source: IDC MarketScape: Worldwide Life Science R&D IT Outsourcing 2011 Vendor Assessment, August 2011

Excerpt from the Report:

• Capabilities: Evaluated on current capabilities and how well aligned it is to customer needs

• Strategies: Indicates how well the company’s future strategy aligns with what customers will require in three to five years

Understanding customer profiles –Market Potential

Pharmaceutical

Biotechnology Consumer

Health Animal Health

Crop Science/Agroc

hemicals

Medical Devices

Dietary Supplements

Cosmetics Tobacco Generics

Turnover > $100m 744 172 63 53 116 128 72 60 46 44

Turnover > $250m 476 123 53 44 100 99 56 52 40 40

Turnover > $500m 351 98 41 38 84 81 43 45 35 32

Turnover > $1b 257 88 34 27 71 60 36 35 29 22

257 88 34 27 71 60 36 35 29 22

351

98 41 38

84 81 43 45 35 32

476

123

53 44

100 99 56 52 40 40

744

172

63 53

116 128

72 60 46 44

0

200

400

600

800

1000

1200

1400

1600

1800

2000

Nu

mb

er

of

com

pan

ies

Customer/prospect type

Number of customers/prospects by type

18

Geographical spread of customers/prospects

North America Europe Africa Asia Australasia South America

Generics 49 17 2 13 0 1

Tobacco 48 13 0 9 0 2

Cosmetics 175 1270 3 661 0 5

Dietary Supplements 150 23 2 34 1 1

Medical Devices 285 79 0 16 0 1

Crop Science/Agrochemicals 166 47 2 104 6 30

Animal Health 120 335 0 95 0 3

Consumer Health 83 27 2 20 0 1

Biotechnology 587 162 0 34 8 0

Pharmaceutical 4018 3757 33 3139 107 185

0

1000

2000

3000

4000

5000

6000

7000

Nu

mb

er

of

cust

om

ers

/pro

spe

cts

Geography

Customers/prospects by geography

19

20

Diverse Customer Base : Life Sciences

Bio-Tech

CROs /

Academic

Pharma

Generics /

OTC

Devices

We serve 7 of top 10 global pharmaceutical companies

Domain Competency

Supply Chain Management

Software Products

SNG, XPC, Resonance

ERM

TAKE IPOINT, Take Forward, Take Hub

Insight, Cameo, Optima

Value Chain Collaboration

Gemini (Process Manufacturing)

Gemini (Discrete Manufacturing)

Compliance Label Manager

RoutePro

Enterprise Mobility & Auto-ID

NAFTAssistant

CAM

e-Request

Global Trade Management

On Premise Products

SaaS Platform

New generation fulfillment on multi-tenancy model

Products in Pipeline

Gemini for SAP

Products in Pipeline Products in Pipeline

GTM on SaaS Platform

OneSCM

TAKE Business Cloud

Social enterprise- perception tracking, Customer insight & service

Products in Pipeline

22

23

Business Services

Spend Analytics

Supplier Performance

Supplier Selection

Contract Administration

Consulting & Insight NAFTA

Compliance

AP automation

Catalog Services

Supplier Enablement

Invoice Processing

Requisition Processing

Reverse Engineering

Value Engineering

Prototyping Simulation & Testing

Design

Drawing & Documentation

Sourcing Support

Sourcing

Engg. Services

Procurement Operations

24

Business Strategy

Augmenting product & service offerings to enhance overall customer experience and business transformation

Investing in new engagement models to drive the demand such as Software as a Service (SaaS)

Increase penetration in high potential geographies (e.g. Europe, Emerging Markets) in addition to consolidation of presence in existing markets (US, Middle East, Asia)

Forging alliances with leading ERP vendors to drive visibility, expand reach & increase volumes

Revenue

– Pent-up demand and revival of investment in ERP is driving software sales

Scalability and functionality advantage in GTM, Auto-ID & Supply Management

Repeat business and longer term engagement

– Outcome oriented end-to-end process outsourcing driving consulting and business services

revenue

100 existing customers in the $1 - 6 Billion (turnover) range provide a captive base for

business services

– Subscription and software as a service driving Supply Chain on the cloud

User adoption crossing 25,000 for OneSCM

New monetization opportunities by leveraging the community

Geographic Reach

– Leverage success of US model in Europe

– Build on the leadership position in the Middle East

Growth Drivers…

25

26

Diverse Customer Base - Global SCM Customers

Pharma & Medical

Industrial Products/ Services

Consumer Products

High Tech

FMCG / Food

Oil & Gas

Financial Highlights

28

Financial Overview

Strong growth and momentum across the operating segments

Revenue (Rs Mn) EBITDA (Rs Mn)

EPS (Rs) PAT (Rs Mn)

* Pre - IPO EPS

1,828

2,967 3,403

3,664

5,061

FY07 FY08 FY09 FY10 FY11

467

793 782 714

1,091

FY07 FY08 FY09 FY10 FY11

316

529 529

324

700

FY07 FY08 FY09 FY10 FY11

3.5

4.74 4.44

2.7

5.82

FY07 FY08 FY09 FY10 FY11 *

29

Revenue Analysis

Revenue By Category Revenue By Geography Revenue By Vertical

73%

63% 65%

27%

37% 33%

2%

FY09 FY10 FY11

US AsiaPac Europe

48% 53%

49%

45% 41%

47%

7% 6% 4%

FY09 FY10 FY11

SCM LS Others

49% 56%

59%

32% 24%

22%

16% 13% 11%

3% 7% 8%

FY09 FY10 FY11

Services Prod Lic & Related Activities AMC Others

30

Group Order Book

18.5 21.5 22.1 23.0

26.6 28.4 28.3 30.3 31.1

22.5

23.8 25.2

26.0

25.2

28.8 33.4

40.5 41.4

0.0

10.0

20.0

30.0

40.0

50.0

60.0

70.0

80.0

Q1 FY10 Q2 FY10 Q3 FY10 Q4 FY10 Q1 FY11 Q2 FY11 Q3 FY11 Q4 FY11 Q1 FY12

USD

mill

ion

SCM LS

41.0

49.0 51.8

57.2

61.7

70.8

45.3 47.3

72.5

31

Share Holding Pattern

Category No of Shares % of Total

Promoter & Promoter Group 71,392,096 58.3%

Public Shareholding

- Institutions

Mutual Funds/Financial Institutions/ Banks

6,788,790 5.5%

FIIs 2,220,276 1.8%

Trust 2,765,422 2.3%

- Non Institutions

Bodies Corporate 16,747,071 13.7%

Retail 22,033,174 18.0%

Others 453,171 0.4%

TOTAL 122,400,000 100.0%

Shareholding Patterns (Jun 30, 2011)

Promoter & Promoter Group,

58.3%

Retail, 18.0%

Bodies Corporate, 13.7%

Mutual Funds/Financial

Institutions/ Banks, 5.5%

Trust, 2.3%

FIIs, 1.8%

Others, 0.4%

Growth Strategies

And

Key TAKEaways

33

Key Growth Strategies

• Remain strongly IP centric :

Plans to launch 6 products across LS and SCM over the next two years

• Build customer focused solutions

• Augment product offerings with services

• Actively pursue emerging technologies & standards and incorporate them in our products

SaaS

Right Product and Service

Mix

• Entry into new geographies

Increase revenue contribution from Europe to 20% over the next two years

• Gain momentum and leadership position in US and Asia Pacific

Exploring New Markets

• Build Partnerships to make our products platform agnostic

DataMAX, Cross Gate, Cegedim Dendrite, Firefox, Intermec, Liquent, Oracle & SAP

• Inorganic Growth for:

Products

Markets

Customers

Right Investments

Growth Enablers

34

Key TAKEaways

Strong fundamentals

Domain expertise

Marquee client list

Niche player operating in niche segments

Strong Portfolio of products and services

Growth momentum

Traction in Life Sciences vertical

Revival in the SCM vertical

Sustained growth in order book providing visibility

Improving financials

Traction in revenue and expansion in margins

Improvement in key operating metrics and profitability ratios

35

Appendix

Acronyms Meanings

CTMS Clinical Trial Management System

EDC Electronic Data Capture

CDMS Clinical Data Management System

eDMS Electronic Document Management System

eSub Electronic Submissions

CDR Clinical Data Repository

LSH Life Sciences Hub

PV Pharmacovigilance

IND Investigational New Drug

CTA Clinical Trial Authorization

NDA New Drug Application

PaaS Platform as a Service

ETL Extract Transform and Load

PO collaboration Purchase Order Collaboration

AP automation Accounts Payables Automation

THANK YOU

Disclaimer:

This presentation has been prepared by TAKE Solutions Ltd. (the “Company”) solely for your information and for your use and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization or firm) or published in whole or in part, for any purpose. By attending this presentation, you are agreeing to be bound by the foregoing restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials.

Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which involve a number of risks, and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, intense competition in IT including factors which may affect our cost advantage, wage increases, our ability to attract and retain highly skilled professionals, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in Supply Chain Management (SCM) & Life Sciences (LS), disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our contracts, withdrawal of governmental fiscal incentives, political instability, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. TAKE does not undertake to update any forward-looking statement that may be made from time to time by or on behalf of the company.

TAKE: Technology, Analytics & Knowledge for the Enterprise

For further information, please contact: Sachin Garg, sachingarg@takesolutions.com